Skip to content
Screener

Absci Corporation ABSI Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$56.16M-84.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$53.01M-34.3%
Assembly Biosciences logo
Assembly BiosciencesASMB
-$9.41M-6.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$36.94M-77.6%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$22.86M-68.8%
Xencor logo
XencorXNCR
-$22.63M+26.8%

Other financials

Income statement

See full
Revenue$318.0K-46.4%
Operating income-$34.2M-8.8%
Net income-$33.2M-8.6%
EPS (diluted)-$0.21+12.5%

Balance sheet

See full
Cash & equivalents$108.9M+97.0%
Total debt$3.7M-32.2%
Total equity$246.1M+42.0%
Total assets$268.9M+28.1%

Cash flow

See full
Operating cash flow-$27.6M-63.4%
CapEx$1.0K-99.6%
Free cash flow-$27.6M-61.2%

Valuation

See full
Market cap$1.51B+268%
Enterprise value$1.41B+290%
P/S969.1×+870×

Profitability

See full
Operating margin-8,084.5%-17,708pp
Net margin-7,756.4%-17,069pp
FCF margin-6,981%-10,936pp

Returns & leverage

See full
Return on equity-57.7%+0.3pp
Debt / equity0.0×
Current ratio10.6×+6.2×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Absci Corporation’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001672688-26-000136
(In thousands, except for share and per share data)For the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Net loss$(33,210)$(30,569)$(62,809)$(56,915)
Net loss per share:Basic and diluted$(0.21)$(0.24)$(0.40)$(0.45)
Weighted-average common shares outstanding:Basic and diluted157,471,712127,592,948155,217,585126,035,844
Comprehensive loss:
Net loss$(33,210)$(30,569)$(62,809)$(56,915)
Foreign currency translation adjustments(52)324(117)401
Unrealized loss on marketable securities(102)(32)(324)(86)
Comprehensive loss$(33,364)$(30,277)$(63,250)$(56,600)

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Absci Corporation's comprehensive income (loss), net of tax, attributable to parent?
Absci Corporation (ABSI) reported comprehensive income (loss), net of tax, attributable to parent of -$33.36M in Q2 2026.
How has Absci Corporation's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Absci Corporation's comprehensive income (loss), net of tax, attributable to parent decreased by 10.2% year-over-year, from -$30.28M to -$33.36M.
What is the long-term trend for Absci Corporation's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Absci Corporation's comprehensive income (loss), net of tax, attributable to parent has grown at a 3.2% compound annual growth rate (CAGR), from -$100.97M to -$114.59M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on securities and foreign currency translation adjustments. It provides a comprehensive view of the company's financial performance beyond traditional net income by capturing all recognized changes in equity. This figure is essential for assessing the total impact of market fluctuations and accounting adjustments on the company's overall financial position.

Ask your AI about Absci Corporation's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude